Patent number: 8202876
Abstract: The invention provides a novel class of compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with abnormal or deregulated kinase activity, particularly diseases or disorders that involve abnormal activation of the Abl, ARG, BCR-Abl, BRK, EphB, Fms, Fyn, KDR, c-Kit, LCK, PDGF-R, b-Raf, c-Raf, SAPK2, Src, Tie2 and TrkB kinases.
Type:
Grant
Filed:
September 24, 2007
Date of Patent:
June 19, 2012
Assignees:
IRM LLC, Novartis AG
Inventors:
Pamela Albaugh, Gregory B. Chopiuk, Qiang Ding, Shenlin Huang, Zuosheng Liu, Shifeng Pan, Pingda Ren, Xia Wang, Xing Wang, Yongping Xie, Chengzhi Zhang, Qiong Zhang, Guobao Zhang, Daniel Poon, Paul Renhowe, Martin Sendzik
Publication number: 20110053932
Abstract: The invention provides compounds and pharmaceutical compositions thereof, which are useful as protein kinase inhibitors, and methods for using such compounds to treat, ameliorate or prevent a condition associated with abnormal or deregulated kinase activity. In some embodiments, the invention provides methods for using such compounds to treat, ameliorate or prevent diseases or disorders that involve abnormal activation of Alk, Abl, Aurora-A, B-Raf, C-Raf, Bcr-Abl, BRK, Blk, Bmx, BTK, C-Kit, C-Raf, C-Src, EphB1, EphB2, EphB4, FGFR1, FGFR2, FGFR3, FLT1, Fms, Flt3, Fyn, FRK3, JAK2, KDR, Lck, Lyn, PDGFR?, PDGFR?, PKC?, p38, Src, SIK, Syk, Tie2 and TrkB kinases.
Type:
Application
Filed:
June 18, 2008
Publication date:
March 3, 2011
Inventors:
Taebo Sim, Truc Ngoc Nguyen, Baogen Wu, Yun He, Yongping Xie, Xing Wang, Guobao Zhang, Nathanael Schiander Gray
Patent number: 7868018
Abstract: The invention provides compounds of Formula I: wherein R1-R6 are described in the Summary of the Invention; the pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with abnormal or deregulated kinase activity, particularly diseases or disorders that involve abnormal activation of the Abl, Bcr-Abl, BMX, BTK, CHK2, b-RAF, c-RAF, CSK, c-SRC, Fes, FGFR3, Flt3, IKK?, IKK?, JNK2?2, Lck, Met, MKK4, MKK6, MST2, NEK2, p70S6K, PDGFR?, PKA, PKB?, PKD2, Rsk1, SAPK2?, SAPK2?, SAPK3, SGK, Tie2 and TrkB kinases.
Type:
Grant
Filed:
August 9, 2006
Date of Patent:
January 11, 2011
Assignee:
IRM LLC
Inventors:
Yongping Xie, Guobao Zhang, Xing Wang, Nathanael S. Gray, Yi Liu
Patent number: 7846923
Abstract: The invention provides a novel class of compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with abnormal or deregulated kinase activity, particularly diseases or disorders that involve abnormal activation of the Abl, Bcr-Abl, Bcr-Abl(T315I), ALK, BLK, BMX, BRK, C-kit, c-RAF, CSK, c-SRC, EGFR, Fes, FGFR3, Flt3, Fms, Fyn, IGF-1R, IR, JAK(2), JAK(3), KDR, Lck, NLK, p70S6K, PDGFR?, Ros, SAPK2?, SGK, SIK, Syk, Tie2 and TrkB kinases.
Type:
Grant
Filed:
May 11, 2007
Date of Patent:
December 7, 2010
Assignee:
IRM LLC
Inventors:
Pingda Ren, Baogen Wu, Guobao Zhang, Yongping Xie, Barun Okram, Victor Nikulin, Xia Wang, Ha-Soon Choi
Publication number: 20100184765
Abstract: The invention provides compounds and pharmaceutical compositions thereof, which are useful as protein kinase inhibitors, and methods for using such compounds to treat, ameliorate or prevent a condition associated with abnormal or deregulated kinase activity. In some embodiments, the invention provides methods for using such compounds to treat, ameliorate or prevent diseases or disorders that involve abnormal activation of Alk, Abl, Aurora-A, B-Raf, C-Raf, Bcr-Abl, BRK, Blk, Bmx, BTK, C-Kit, CSK, C-Src, EphB1, EphB2, EphB4, FLT1, Fms, Flt3, Fyn, FRK3, JAK2, KDR, Lck, Lyn, PDGFR?, PDGFR?, PKC?, SAPK2?, Src, SIK, Syk, Tie2 and TrkB kinases.
Type:
Application
Filed:
June 10, 2008
Publication date:
July 22, 2010
Inventors:
Shenlin Huang, Zuosheng Liu, Pamela A. Albaugh, Xing Wang, Shifeng Pan, Yongping Xie, Guobao Zhang
Publication number: 20100048552
Abstract: The invention provides a novel class of compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with abnormal or deregulated kinase activity, particularly diseases or disorders that involve abnormal activation of the Abl, Bcr-Abl, Bcr-Abl(T315I), ALK, BLK, BMX, BRK, C-kit, c-RAF, CSK, c-SRC, EGFR, Fes, FGFR3, Flt3, Fms, Fyn, IGF-1R, IR, JAK(2), JAK(3), KDR, Lck, NLK, p70S6K, PDGFR?, Ros, SAPK2?, SGK, SIK, Syk, Tie2 and TrkB kinases.
Type:
Application
Filed:
May 11, 2007
Publication date:
February 25, 2010
Applicant:
IRM LLC
Inventors:
Pingda Ren, Baogen Wu, Guobao Zhang, Yongping Xie, Barun Okram, Victor Nikulin, Xia Wang, Ha-Soon Choi
Publication number: 20100029605
Abstract: The invention provides a novel class of compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with abnormal or deregulated kinase activity, particularly diseases or disorders that involve abnormal activation of the Abl, ARG, BCR-Abl, BRK, EphB, Fms, Fyn, KDR, c-Kit, LCK, PDGF-R, b-Raf, c-Raf, SAPK2, Src, Tie2 and TrkB kinases.
Type:
Application
Filed:
September 24, 2007
Publication date:
February 4, 2010
Applicants:
Novartis AG
Inventors:
Pamela Albaugh, Gregory S. Chopiuk, Qiang Ding, Shenlin Huang, Zuosheng Liu, Shifeng Pan, Pingda Ren, Xia Wang, Xing Wang, yongping Xie, Chengzhi Zhang, Qiong Zhang, Guobao Zhang, Daniel Poon, Paul Renhowe, Martin Sendzik
